336 related articles for article (PubMed ID: 32651718)
1. [
Nakajo M; Jinguji M; Tani A; Kajiya Y; Nandate T; Kitazano I; Yoshiura T
Mol Imaging Biol; 2020 Dec; 22(6):1609-1620. PubMed ID: 32651718
[TBL] [Abstract][Full Text] [Related]
2. 18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry.
Mapelli P; Bettinardi V; Fallanca F; Incerti E; Compierchio A; Rossetti F; Coliva A; Savi A; Doglioni C; Negri G; Gianolli L; Picchio M
Curr Radiopharm; 2018; 11(1):50-57. PubMed ID: 29119942
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
[TBL] [Abstract][Full Text] [Related]
4.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
5. Relationship between clinicopathologic factors and FDG avidity in radioiodine-negative recurrent or metastatic differentiated thyroid carcinoma.
Ha LN; Iravani A; Nhung NT; Hanh NTM; Hutomo F; Son MH
Cancer Imaging; 2021 Jan; 21(1):8. PubMed ID: 33413689
[TBL] [Abstract][Full Text] [Related]
6. Correlation analysis of [
Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
Acta Oncol; 2017 Sep; 56(9):1181-1188. PubMed ID: 28537761
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
[TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
Sabet A; Binse I; Grafe H; Ezziddin S; Görges R; Poeppel TD; Bockisch A; Rosenbaum-Krumme SJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
[TBL] [Abstract][Full Text] [Related]
11. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
12. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
13. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
14.
Fu H; Wu J; Huang J; Sun L; Wu H; Guo W; Qiu S; Chen H
Radiology; 2022 Aug; 304(2):397-405. PubMed ID: 35536131
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.
Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Tanimoto K; Horiike A; Yanagitani N; Ohyanagi F; Nishio M
Cancer Sci; 2015 Nov; 106(11):1554-60. PubMed ID: 26292100
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma.
Kang SY; Bang JI; Kang KW; Lee HY; Chung JK
PLoS One; 2019; 14(6):e0218416. PubMed ID: 31237886
[TBL] [Abstract][Full Text] [Related]
18. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
[TBL] [Abstract][Full Text] [Related]
19. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
